NEW YORK, July 26 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) will apply for approval to sell a new heart treatment as a single pill, rather than only in combination with its top selling Lipitor, the New York Times reported on Wednesday, quoting a company executive. The new drug, torcetrapib, is still being tested in clinical trials and is at least 18 months from federal approval, but cardiologists say it has potential to become a significant new treatment for heart disease, the report said.
